Summary & Overview
HCPCS Q5139: Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
HCPCS Level II code Q5139 denotes an injection of eculizumab-aeeb (bkemv), a biosimilar formulation dosed per 10 mg. This code captures administration of a high-cost monoclonal antibody biosimilar used in specialized immunologic and hematologic conditions, making it a focus for national payer coverage policies, utilization management, and site-of-service planning. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication summarizes payer coverage themes and considerations, common billing modifiers encountered for biologic injections, and related operational benchmarks such as infusion setting and billing practices. It also outlines policy and reimbursement issues that influence access and billing for biosimilar monoclonal antibodies. Where specific data points are not available in the input, the text notes the absence of those details. The goal is to provide clinicians, billing managers, and policy stakeholders a clear, national-level briefing on HCPCS Level II code Q5139 to inform coding, billing, and coverage discussions.
Billing Code Overview
HCPCS Level II code Q5139 represents an injection of eculizumab-aeeb (bkemv), biosimilar, 10 mg. The service is an intravenous biologic infusion/injection used to deliver a biosimilar form of eculizumab. The typical site of service for this medication is an outpatient infusion center, hospital outpatient department, or physician office infusion suite, depending on payer and clinical setting.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a complement-mediated disorder (for example, paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome) who requires intravenous administration of a monoclonal antibody biosimilar, Q5139 (eculizumab-aeeb, 10 mg). The workflow begins with outpatient specialty clinic or infusion center referral from a hematologist or nephrologist. Pre-infusion steps include verification of diagnosis, review of prior vaccination status (meningococcal immunization), baseline laboratory studies (CBC, renal function, LDH), and consent. On the day of service, nursing conducts pre-medication assessment, documents vital signs and allergy status, and establishes intravenous access. The infusion is prepared by pharmacy and administered by trained infusion nurses in a monitored outpatient infusion suite or hospital outpatient infusion center. During infusion, staff monitor for infusion reactions and complement-related adverse events, with medication held or slowed per protocol if reactions occur. Post-infusion observation is completed, documentation of lot number and units administered is recorded, and follow-up dosing schedule is arranged. Typical site of service: outpatient infusion center, hospital outpatient department, or skilled nursing facility for patients requiring supervision during therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |